Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CPI-169 + RN-1|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CPI-169||EZH2 inhibitor 18||CPI-169 inhibits EZH2, resulting in reduced H3K27 tri-methylation, and potentially leading to decreased tumor cell proliferation and reduced tumor growth (PMID: 25457180).|
|RN-1||KDM1A Inhibitor 12||RN-1 irreversibly inhibits KDM1A, potentially resulting in decreased tumor cell growth (PMID: 26837761).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute myeloid leukemia||not applicable||CPI-169 + RN-1||Preclinical - Cell culture||Actionable||In a preclinical study, RN-1 and CPI-169 demonstrated synergy in growth inhibition of several acute myeloid leukemia cell lines in culture (PMID: 26837761).||26837761|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|